相似文献
1
TOR-inhibitors as gero-suppressors.
Aging (Albany NY). 2015 Dec;7(12):1030-1. doi: 10.18632/aging.100869.
2
Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Adv Biol Regul. 2015 Jan;57:64-74. doi: 10.1016/j.jbior.2014.09.004. Epub 2014 Sep 18.
3
Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components.
Semin Cell Dev Biol. 2014 Dec;36:140-6. doi: 10.1016/j.semcdb.2014.09.018. Epub 2014 Sep 27.
4
Inhibition of TORC1 signaling and increased lifespan: gained in translation?
Aging (Albany NY). 2013 May;5(5):335-6. doi: 10.18632/aging.100560.
5
mTOR inhibition in T-cell lymphoma: a path(way) forward.
Blood. 2015 Jul 16;126(3):284-6. doi: 10.1182/blood-2015-05-644724.
6
The use of calorie restriction mimetics to study aging.
Methods Mol Biol. 2013;1048:95-107. doi: 10.1007/978-1-62703-556-9_8.
7
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
J Gerontol A Biol Sci Med Sci. 2016 Jul;71(7):841-9. doi: 10.1093/gerona/glw090. Epub 2016 May 21.
8
mTOR in aging, metabolism, and cancer.
Curr Opin Genet Dev. 2013 Feb;23(1):53-62. doi: 10.1016/j.gde.2012.12.005. Epub 2013 Jan 11.
9
Cellular and molecular effects of the mTOR inhibitor everolimus.
Clin Sci (Lond). 2015 Nov;129(10):895-914. doi: 10.1042/CS20150149.
10
[mTORC1 and sirolimus: a link with fertility].
Med Sci (Paris). 2013 Feb;29(2):200-5. doi: 10.1051/medsci/2013292019. Epub 2013 Feb 28.
引用本文的文献
1
Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.
Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.
本文引用的文献
1
Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Oncotarget. 2015 Sep 15;6(27):23238-48. doi: 10.18632/oncotarget.4836.
2
Rejuvenating immunity: "anti-aging drug today" eight years later.
Oncotarget. 2015 Aug 14;6(23):19405-12. doi: 10.18632/oncotarget.3740.
3
Koschei the immortal and anti-aging drugs.
Cell Death Dis. 2014 Dec 4;5(12):e1552. doi: 10.1038/cddis.2014.520.
4
Rapamycin-induced metabolic defects are reversible in both lean and obese mice.
Aging (Albany NY). 2014 Sep;6(9):742-54. doi: 10.18632/aging.100688.
5
Rapamycin in preventive (very low) doses.
Aging (Albany NY). 2014 Mar;6(3):158-9. doi: 10.18632/aging.100645.
6
BMAL1-dependent regulation of the mTOR signaling pathway delays aging.
Aging (Albany NY). 2014 Jan;6(1):48-57. doi: 10.18632/aging.100633.
7
Rapamycin extends life- and health span because it slows aging.
Aging (Albany NY). 2013 Aug;5(8):592-8. doi: 10.18632/aging.100591.
8
Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance.
Aging (Albany NY). 2013 Jul;5(7):539-50. doi: 10.18632/aging.100576.
9
Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to.
Aging (Albany NY). 2012 May;4(5):350-8. doi: 10.18632/aging.100461.
Zotero 插件